Merck researchers gave 25 data presentations that focused on Merck's infectious disease medicines at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held April 22-25 in Vienna, Austria.
“Infectious diseases remain one of the great public health threats in the world today," Merck Research Laboratories Vice President of Infectious Disease Clinical Research Nicholas Kartsonis said in a Merk release. "At Merck, we have never wavered in our commitment to invest in developing anti-infective therapies that prevent and treat serious infectious diseases. We also continue to collaborate with researchers, clinicians and other stakeholders worldwide to advocate for responsible use of these important medicines.”
The presentations included an oral presentation on the topline data from the Phase III study evaluating letermovir in the treatment of cytomegalovirus (CMV). The participants were CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants. The clinical trial began in July 2014.
Other presentations included data on ZERBAXA (ceftolozane and tazobactam) and Imipenem/Relebactam.
ZERBAXA is approved for use in the U.S. The antibacterial combination is used intravenously for complicated urinary tract infections (cUTI) caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and other microorganisms.
ZERBAXA is also used in combination with metronidazole for complicated intra-abdominal infections (cIAI) caused by microorganisms including Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa and Streptococcus.
